Riely, Gregory J.; Wood, Douglas E.; Aisner, Dara L.; Axtell, Andrea L.; Bauman, Jessica R.; Bharat, Ankit; Chang, Joe Y.; Desai, Aakash; Dilling, Thomas J.; Dowell, Jonathan; Durm, Gregory A.; Gettinger, Scott; Grotz, Travis E.; Gubens, Matthew A.; Juloori, Aditya; Lackner, Rudy P.; Lanuti, Michael; Levy, Benjamin; Lin, Jules; Loo, Billy W., Jr.; Lovly, Christine M.; Maldonado, Fabien; Morgensztern, Daniel; Mullikin, Trey C.; Ng, Thomas; Owen, Dawn; Owen, Dwight H.; Patil, Tejas; Polanco, Patricio M.; Riess, Jonathan; Mendez, Ana Lucia Ruano; Shapiro, Theresa A.; Singh, Aditi P.; Stevenson, James; Tam, Alda; Tanvetyanon, Tawee; Yanagawa, Jane; Yau, Edwin; Yun, Karen; Gregory, Kristina; Hang, Lisa (2026).听.听Journal of the National Comprehensive Cancer Network, 24(4).听
罢丑别听NCCN Clinical Practice Guidelines in Oncology听蹿辞谤听non-small cell lung cancer (NSCLC)聽provide evidence-based recommendations to help doctors manage this common type of lung cancer. These guidelines cover the full course of care, including how the disease is diagnosed, treated initially, monitored over time (surveillance), and managed if it progresses. In this update, the expert panel has revised the list of recommended聽targeted therapies鈥攖reatments designed to specifically attack cancer cells with certain genetic features鈥攂ased on the latest approvals from the U.S. Food and Drug Administration (FDA) and new clinical research findings. This section of the guidelines focuses on patients with聽advanced or metastatic NSCLC聽(cancer that has spread beyond the lungs) whose tumors have聽actionable biomarkers, meaning identifiable genetic mutations or molecular traits that can be matched with specific targeted treatments to improve outcomes.
Figure 1.
NSCL-19. NCCN Clinical Practice Guidelines in Oncology for Non鈥揝mall Cell Lung Cancer, Version 4.2026.